RE:RE:Didn't the little boy who cried wolf...Hi GV.
GV wrote - "Why a 3rd partner.??" - GV, would you really want Eastern to even take a greater position of power? Personally with me that would be OK but a third partner adds more independence and is a significant benefit to retail share holders because there is no way that Eastern, NGN and Shenzhen Hepalink would be able to get together and collude against small shareholders.
- Don is playing a beautiful chess game here. I think he understands his strengths full well so now he is building value to Resverlogix with each of these types of deals and thus raising the price for BP to get in. For example, before this deal all RVX had was rvx-208 and the hope that Ph3 BETonMACE succeeds. Now it has a development and distribution partner that clearly believes rvx-208 will succeed and gives access to a huge and sophisticated group of populations.
I'm looking forward to the announcement of the next development and distribution partner because as each one is added it will make this asset far more expensive for BP to acquire. The world is a big place and there are lot's of countries to supply.
The story adds up beautifully because it clearly indicates that Eastern and NGN recognize the value of a number of factors including;
- The scientific intellectual capital being brought to the party by S Hepalink.
- Development and distribution of rvx-208 in China, Hong Kong, Taiwan and Macau. Hence a huge chunk of the worlds population, with massive problems with diabetes melliteus to be served by rvx-208.
- Obviously it indicates how Eastern and NGN recognize how big the pie is and they are looking for mechanisms to accelerate access and revenue flow to RVX.
- Eastern and NGN are capital companies. They want to see huge growth in shareholder equity just like the rest of us.
I think that tundup covered the idea of "management doing a deal and screwing the retail shareholders" in a very clear and concise manner.
Eastern, NGN and now Hepalink are all shareholders just like us. So Don, with his 5.3% of the shares really can't pull off some sort of management deal.
Buy the way, I don't believe for one minute that Don would even think of it!
THINK BIG FOLKS...THINK VERY BIG!!! THINGS ARE ACCELERATING FASTER THAN I'VE EVER SEEN!!! EPIGENETICS IS THE NEW FRONTIER AND DON CLAIMS THAT RVX HAS BEEN AT IT FOR MORE THAT 8 YEARS AS EVIDENCED BY ZENITH EPIGENETICS.
What I keep in mind from the ASSURE trial is the following;
- Total Atheroma Volume (TAV) reduction was met at the highly significant level of p = 0.001.
- 10mm worst occluded TAV reductions were highly significant at p = 0.001.
- HDL increase target was met at a highly statistically significant level with 10.73% increase significant at p = 0.001.
- APOA-I increase of 11.69% was significant at p = 0.001.
These were secondary indicators pre-defined in the trial and are not "post hoc" constructions. They were part of the experimental design.
So, as a side benefit (hahaha) HDL (thus APOA-I) is highly involved in the production of testosterone and we all know with the sales of Viagra in America that there is a serious testosterone problem happening! LOL but serious! What will rvx-208 do for our sex lives? We may be very happy when this gets to market.
This is all to say the following. We all know the phase 3 trial called BETonMACE is directed at patients with diabetes mellitus with CVD and low HDL and that this is a huge and growing population in North America none the less the world. My sense is that the epigenetic drug called rvx-208 and it's variations goes well beyond just this huge population.
I believe in the science and I support my beliefs by the quality of scientific interests involved in this organization both internally and beyond including NGN, Eastern and now Shenzhen Hepalink and there will be others.
Now, in the combined post hock ASSURE/SUSTAIN trials in the diabetes mellitus patients with cardiovascular disease and low HDL the relative risk reduction (RRR) of major adverse cardiovascular events (MACE) was 77% at day 210 of dosing.
- If I ever have these conditions I know that I want to be in the test group (rvx-208 + rosuvastatin) because their MACE was approximately 5% vs. the control group with MACE at 21%.
My apologies to readers of this post because I put it together rather hastily and would have liked to have constructed it with more rigour. Anyway, just hit the skip button if it bores you.
As everyone knows I'm long and positively biased. With the Hepalink (potential) deal I am more convinced than ever and I hope Don brings more partners to the party.
Regarding BETonMACE based on the last info I read on this the target is 30% RRR. The post hoc analysis achieved 77% with p = 0.01. This seems to bode well for success!
DYODD GLTA
Cheers
Toinv :)